Modality
Fusion Protein
MOA
AuroraAi
Target
PCSK9
Pathway
Notch
SLEHeart Failure
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
~Oct 2021
→ ~Jan 2023
Phase 2
Apr 2023
→ May 2030
Phase 2Current
NCT08517935
318 pts·Heart Failure
2023-04→2030-05·Recruiting
318 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-05-174.1y awayPh3 Readout· Heart Failure
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-05-17 · 4.1y away
Heart Failure
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08517935 | Phase 2/3 | Heart Failure | Recruiting | 318 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 |